Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose

Background: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate the effective...

Full description

Bibliographic Details
Main Authors:	Cutlip, D.E (Author), Deliargyris, E.N (Author), Doros, G. (Author), Gibson, C.M (Author), Kroger, H. (Author), Lee, V.T (Author), Mack, M.J (Author), Ohman, E.M (Author), Schneider, D.J (Author), Sellke, F.W (Author), Thourani, V.H (Author)
Format:	Article
Language:	English
Published:	Elsevier Inc. 2022
Subjects:	acetylsalicylic acid adult Article cardiopulmonary bypass controlled study double blind procedure drug blood level enoxaparin erythrocyte transfusion EuroSCORE experimental therapy female follow up heart muscle revascularization human intraoperative period low molecular weight heparin major clinical study male mass spectrometry outcome assessment perioperative period postoperative hemorrhage postoperative period prospective study randomized controlled trial safety thorax surgery thrombocyte transfusion ticagrelor
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Internet

Similar Items